- NeoStem (NBS) has received the first two European patents for its CD34 Cell program, in which the company is developing treatments for ischemia, when the supply of oxygenated blood in the body is restricted.
- The IP is for "Compositions and Methods of Vascular Injury Repair."
- The CD34 program now has 16 granted and allowed patents around the world. (PR)
at Zacks.com (Tue, 9:46AM)